Apellis Pharmaceuticals, which is developing a novel protein inhibitor for autoimmune and inflammatory diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering.
The Crestwood, KY-based company was founded in 2009 and plans to list on the Nasdaq under the symbol APLS. Apellis Pharmaceuticals filed confidentially on August 19, 2015. Citi and J.P. Morgan are the joint bookrunners on the deal. No pricing terms were disclosed.
